Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enbrel etanercept: Phase III data; marketed to treat rheumatoid arthritis (RA) and psoriatic arthritis

In a double-blind, U.S. Phase III trial in 583 patients, 49% of patients given 50

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE